iBreastExam
Commercial- Indications
- Breast cancer screening
Company intelligence / Profile preview
UE LifeSciences has developed and commercialized non-invasive, portable devices for early breast, cervical, and oral cancer screening. Their flagship product iBreastExam has been FDA cleared and CE marked; it has screened over a quarter million women in more than two dozen countries. Clinical results show high efficacy in detecting breast lumps with minimal training required for operators. The company’s new products—cervAIcal and OrCA—extend this approach to cervical and oral cancers respectively. These solutions are validated through global pilots and partnerships with leading healthcare organizations.
3 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on UE LifeSciences.